Associated vaccine against colibacteriosis, salmonellosis, streptococcosis and enterococcal infection in nutrias

FIELD: veterinary medicine.

SUBSTANCE: the vaccine suggested contains as antigens: the cell suspension of pure cultures of Escherichia coli, Salmonella typhimurium and Streptococcus fecalis obtained due to selecting the affected organs from dead nutrias out of local epizootic focus, preparing the suspension, inoculation onto differential-diagnostic media, isolating pure cultures of the agents of Escherichia coli, Salmonella typhimurium and Streptococcus fecalis. The obtained pure cultures of microorganisms should be separately grown in beef-extract broth with glucose up to the concentration of microbial cells being 4-5 bln/cu. cm to be then mixed at equal ratios. The vaccine, also, contains formalin, glucose and aluminum hydroxide at the following ratio of the components, weight%: cell suspension of Escherichia coli pure culture isolated from the affected organs out in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu. cm 18.0-21.0; cell suspension of Salmonella typhimurium pure culture isolated from the affected organs in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu. cm 18.0-21.0, cell suspension of Streptococcus pneumoniae pure culture isolated from the affected organs in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu/ cm 18.0-21.0 cell suspension of Streptococcus fecalis pure culture isolated from the affected organs in dead nutrias out of local epizootic focus in nutritive medium at the titer being 4-5 bln microbial cells/cu. cm 18.0-21.0, glucose 2.0-1.0; formalin 2.0-1.5; aluminum hydroxide - the rest. The vaccine in question is of high specificity, safety and immunogenicity.

EFFECT: higher efficiency.

5 ex, 1 tbl

 

The invention relates to veterinary medicine, in particular for vaccines and can be used in institutions for the construction of biological products, as well as enterprises of biological industry.

Known associated vaccine against diarrhea of calves containing bacterial cells of Escherichia strains: 0138 C, C, 200; Salmonella strains: risk No. 195, GISC No. 196, GISC No. 197; Proteus, strains: risk No. 198, GISC No. 199; Klebsiella strains: risk No. 201, GISC No. 202 (patent RF №2035916 from 17.06.93, MKI A61 39/125, 39/135). The vaccine is intended for the prevention of infectious diseases in calves caused by Escherichia, Salmonella, Proteus and Klebsiella, nutria does not apply.

Known vaccine against Streptococcus and pasteurellosis nutria (RF patent for the invention №2099083 from 30.09.94, MKI AC 39/125, 39/135). This vaccine contains as antigen suspension of a strain of Streptococcus zooepidemicus VGNKI # K-DEPT with a titer of 2.5-3.0 billion microbial cells in 1 ml culture medium, a cell suspension of strains of Pasteurella multosida VGNKI No. 6011, Pasteurella multosida VGNKI No. 2394 and Pasteurella multocida VGNKI No. 1015 in equal proportions by the total content of 2.5-3.0 billion microbial cells in 1 ml of culture medium glucose, formalin, aluminum hydroxide and saponin. This vaccine is indicated for prevention of Streptococcus and pasteurellosis nutria. Raw material received is t by culturing strains of Streptococcus and pasteurellosis nutria in a nutrient medium with low activity. The use of saponin in the vaccine causes in vaccinated animals of different post-vaccination complications (inflammation, abscesses at the injection site, lameness and other)

The technical solution of the invention is to remedy these shortcomings, in particular improving the specificity, efficacy of vaccine for the prevention of colibacillosis, salmonellosis, streptococcosis and Enterococcus infection in nutria, through the introduction of new crops pathogens, components, excluding the adverse effect.

The solution is achieved by the fact that the vaccine is associated against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria, including inactivated antigens, adjuvant, as antigens includes: the suspension of cells in pure cultures of pathogens Escherichia coli. Salmonella typhimurium, Streptococcus pneumoniae and Streptococcus fecalis, obtained by selection of the affected organs from dead nutria from local epizootic focus, slurry preparation, sowing on differential diagnostic environment, isolation of pure cultures of pathogens Escherichia coli, Salmonella typhimurium, Streptococcus pneumoniae and Streptococcus fecalis and cultivation is conducted separately in meat-peptone broth with glucose to a concentration of microbial cells 4-5 billion in 1 cm3mixed in equal proportions, contribute formalin and gidroksilamina in the following ratio of components, wt.%:

a cell suspension of a pure culture of the pathogen Escherichia coli isolated from diseased organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm318,0-21,0;

a cell suspension of a pure culture of the pathogen Salmonella typhimurium isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm318,0-21,0;

a cell suspension of a pure culture of the pathogen Streptococcus pneumoniae isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm318,0-21,0;

a cell suspension of a pure culture of the pathogen Streptococcus fecalis, isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells

1 cm318,0-21,0
glucose2,0-1,0
formalin2,0-1,5
aluminium hydroxidethe rest of it.

The novelty of the claimed technical solution due to the fact that in contrast to the known vaccines for obtaining raw materials shall conduct sampling of the affected organs from dead nutria from local e isotechnika hearth, preparation of a suspension culture of differential diagnostic environment, isolation of pure cultures of pathogens Escherichia coli, Salmonella typhimurium, Streptococcus pneumoniae and Streptococcus fecalis, cultivation of pure cultures of pathogens are organized separately in meat-peptone broth, which improves the specificity and immunogenicity.

During separate cultivation of pure cultures of pathogens and adding to the culture medium of glucose and 0.2%concentration allows the concentration of microbial cells at least 4-5 billion in 1 ml for 12-14 hours incubation. Inaktivirovanie bacteria formalin 0.4 to 0.5%final concentration at a temperature of 37°C for 72-96 hours can suppress pathogenic agents and to retain their immunogenic properties within 12 months. Mixing inactivated cultures of pathogens Escherichia coli colibacillosis, salmonellosis Salmonella typhimurium, Streptococcus Streptococcus pneumoniae and Enterococcus infection Streptococcus fecalis in equal proportions, making aluminium hydroxide and thorough mixing does not cause grafted nutria post-vaccination complications, allows to ensure the formation of a busy immunity after 12-15 days after a single injection of a minimum duration of 9 months (observation period). The use of pure cultures of pathogens colibacillosis Eschericia coli, salmonellosis Salmonella typhimurium, Streptococcus Streptococcus pneumoniae and Enterococcus infection Streptococcus fecalis, isolated from local epizootic focus from sick and dead nutria, can significantly improve the specificity of the vaccine after a single vaccination protects animals directly from four of dangerous infectious diseases colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria.

According to the patent and scientific literature not found a similar set of features, components, allowing to judge about the inventive step of the claimed technical solution.

As for the criterion "industrial applicability", the components included in the vaccine, well-known and widely used in veterinary practice in the manufacture of inactivated vaccines: formalchemy vaccine against paratyphoid (salmonellosis) calves THAT 46-21-166-75, approved 10.05.75, instructions for the manufacture and control of this vaccine approved by the Main veterinary Department Ministry of agriculture of the USSR 28.03.80 year; vaccine against paratyphoid (salmonellosis) piglets THAT 46-21-952-74, approved 15.07.74, the instructions for the manufacture and control of this vaccine approved by the Main veterinary Department Ministry of agriculture of the USSR 23.10.96 year; the associated vaccine against salmonellosis, pasteurellosis and Enterococcus infection then the heel THAT 10.09-62-90, approved 01.08.90, the instructions for the manufacture and control of this vaccine approved by the Main veterinary Department 16.07.90 year; vaccine Enterococcus infection of calves, lambs and piglets THAT 10.09-91-90, approved 15.12.90, But for nutria these vaccines are not applied.

Methods of isolation of pure culture of the pathogen colibacillosis and characterization are described in the "guidelines for bacteriological diagnosis of colibacillosis (escherichiosis) animals"approved 27.07.2000, No. 13-7-2/2117, the veterinary Department of the Ministry of agriculture of the Russian Federation, described the characteristics of Escherichia reference "Determinant zoopathogenic microorganisms edited by Professor Sidorov M.A., Moscow, Kolos, 1995, str-201, as well as in the "Workshop on veterinary Microbiology and immunology" authors: Kostenko T.S., Rodionova V.B. have been, Skorodumov DI, M.: Kolos, 2001, sett. 219-222.

Methods of isolation and characterization of Salmonella described in the guidance "Laboratory diagnosis of Salmonella infections of man and animals, detection of Salmonella in feed, food products and objects of the external environment". Moscow, VO "Agropromizdat", 1990, as well as in the directory "Determinant zoopathogenic microorganisms edited by Professor Sidorov M.A., Moscow, Kolos, 1995, str-204. In "Workshop on veterinary Microbiology and immunology" authors: Kostenko T.S., Rodionova V.B. have been, Skorodumov D., M: "Kolos", 2001, str-231.

Methods of isolation and characterization of Streptococcus presented in "guidelines for laboratory diagnosis of Streptococcus animals"approved 25.09.1990,, Main Directorate of veterinary state Inspectorate under the State Commission of the USSR food and procurement, as well as in the directory "Determinant zoopathogenic microorganisms edited by Professor Sidorov M.A., Moscow, Kolos, 1995, p.90-95.

The proposed vaccine associated against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria, simple, affordable, and is industrially applicable.

Vaccine associated against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria, contains formalin inactivated pure cultures of pathogens Escherichia coli colibacillosis, salmonellosis Salmonella typhimurium, Streptococcus Streptococcus pneumoniae and Enterococcus infection Streptococcus fecalis, adsorbed on the hydrate of aluminum oxide. In appearance the vaccine is a liquid light yellow color with loose sediment, which when shaken can be easily broken in a homogeneous suspension. The period of storage in a dry, dark place at temperatures from 2 to 10°1 year. The vaccine is intended for the prevention of infectious diseases of chickpea is the third against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria. It causes the formation of specific immunity against colibacillosis, salmonellosis and Enterococcus infection nutria. The vaccine is harmless and reactogenic. Immunity nutria, vaccinated vaccine against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria, is formed through 12-15 days after vaccination and lasts at least 9 months. The vaccine is applied in a safe, unsafe and threatened by colibacteriosis, salmonellosis, streptococcosis and Enterococcus infection nutria farms. In the prosperous and threatened to colibacteriosis, salmonellosis, streptococcosis and Enterococcus infection nutria farms vaccines injected once intramuscularly in the thigh, to the youngsters from the age of 45 days for 1.0 cm3and adult animals to 1.5 cm3. Disadvantaged farms vaccine intramuscularly in the thigh with 2 months of age twice with an interval of 7-10 days: the first vaccination dose of 1.0 cm3second, in the dose of 1.5 cm3. Products of slaughter vaccinated nutria use without restriction regardless of the timing of vaccination.

The determinants of receiving the vaccine given property include construction sequence and the percentage ratio between the components is Tami, included in the product.

The above five examples, containing components in various proportions for 100 ml of the vaccine.

Example 1

Take the affected organs from dead nutria from local epizootic foci, of which prepare the suspension, do the planting on differential diagnostic environment, isolated pure culture of Escherichia coli. Salmonella typhimurium. Streptococcus pneumoniae and Streptococcus fecalis, separately cultivated, receive, disable, and mixed (wt.%) a suspension of microbial cells 68,0, with the title of 4-5 billion and glucose, 0.5 to inactivate making formalin 1.0, then add the aluminum hydroxide - rest, thoroughly mix and get the vaccine of the following composition in the following ratio, wt.%:

a cell suspension of a pure culture of the pathogen Escherichia coli isolated from diseased organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm317,0;

a cell suspension of a pure culture of the causative agent of salmonellosis Salmonella typhimurium isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm317,0;

a cell suspension of a pure culture of the pathogen Streptococcus Streptococcus pneumoniae isolated from affected organs from dead nutria from local episodes the political focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm 317,0;

a cell suspension of a pure culture of the pathogen Enterococcus infection Streptococcus fecalis, isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells

1 cm3of 17.0
glucose0,5
formalin1,0
aluminium hydroxidethe rest of it.

When this ratio of the components of the vaccine associated against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria, has weak immunogenic activity.

Example 2

Take the affected organs from dead nutria from local epizootic foci, of which prepare the suspension, do the planting on differential diagnostic environment, isolated pure culture of Escherichia coli., Salmonella typhimurium. Streptococcus pneumoniae and Streptococcus fecalis, separately cultivated, receive, disable, and mixed (wt.%) a suspension of microbial cells 72,0, with the title of 4-5 billion and glucose content of 1.0 inactivate making formalin is 1.5, then add the aluminum hydroxide - rest, thoroughly mix and get the vaccine of the following composition in the following ratio, wt.%:

the suspension of cells is pure cult the fish pathogen Escherichia coli, isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm318,0;

a cell suspension of a pure culture of the causative agent of salmonellosis Salmonella typhimuriu isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm318,0;

a cell suspension of a pure culture of the pathogen Streptococcus Streptococcus pneumoniae isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm318,0;

a cell suspension of a pure culture of the pathogen Enterococcus infection Streptococcus fecalis, isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells

1 cm318,0
glucose1,0
formalin1,5
aluminium hydroxidethe rest of it.

When this ratio of the components of the vaccine associated against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria has good immunogenic activity.

Example 3

Take the affected organs from dead nutria from local epizootic foci, of which prepare the suspension, do the planting on differential diagnostic environment, isolated pure culture of Escherichia coli., Salmonella typhimurium, Streptococcus pneumoniae and Streptococcus fecalis, isolated from local epizootic focus, separately cultivated, receive, disable, and mixed (wt.%) a suspension of microbial cells 76,0 with titer 4-5 billion, and glucose content of 1.7, inactivate making formalin 1,3, then add the aluminum hydroxide - rest, thoroughly mix and get the vaccine of the following composition in the following ratio, wt.%:

a cell suspension of a pure culture of Escherichia coli isolated from diseased organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm319,0;

a cell suspension of a pure culture of Salmonella typhimurium isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm319,0;

a cell suspension of a pure culture of Streptococcus pneumoniae isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm319,0;

a cell suspension of a pure culture of Streptococcus fecalis, selected from orogennykh organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells

1 cm319,0
glucose1,7
formalin1,3
aluminium hydroxidethe rest of it.

When this ratio of the components of the vaccine associated against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria, has minor immunogenic efficiency.

Example 4

Take the affected organs from dead nutria from local epizootic foci, of which prepare the suspension, do the planting on differential diagnostic environment, isolated pure culture of Escherichia coli, Salmonella typhimurium, Streptococcus pneumoniae and Streptococcus fecalis, isolated from local epizootic focus, separately cultivated, receive, disable, and mixed (wt.%) a suspension of microbial cells 84,0, with the title of 4-5 billion, and glucose content of 1.0 inactivate making formalin is 1.5, then add the aluminum hydroxide - rest, thoroughly mix and get the vaccine of the following composition in the following ratio, wt.%:

a cell suspension of a pure culture of Escherichia coli isolated from diseased organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm321,0;

suspen the s cells of pure cultures of Salmonella typhimurium, isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm321,0;

a cell suspension of a pure culture of Streptococcus pneumoniae isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm321,0;

a cell suspension of a pure culture of Streptococcus fecalis, isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells

1 cm321,0
glucose1,0
formalin1,5
aluminium hydroxidethe rest of it.

When this ratio of the components of the vaccine associated against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria, has a high immunogenic activity, forms after vaccination expressed intense immunity, does not cause vaccine-related complications, stable during storage for 12 months (table 1).

Example 5

Take the affected organs from dead nutria from local epizootic foci, of which prepare the suspension, do the planting on the WPPT is erentielle diagnostic environment, allocate a pure culture of Escherichia coli, Salmonella typhimurium. Streptococcus pneumoniae and Streptococcus fecalis, isolated from local epizootic focus, separately cultivated, receive, disable, and mixed (wt.%) a suspension of microbial cells 88,0 with titer 4-5 billion and glucose content of 2.0, inactivate making formalin is 1.5, then add the aluminum hydroxide - rest, thoroughly mix and get the vaccine of the following composition in the following ratio, wt.%:

a cell suspension of a pure culture of Escherichia coli isolated from diseased organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm322, 0mm;

a cell suspension of a pure culture of Salmonella typhimurium isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm322, 0mm;

a cell suspension of a pure culture of Streptococcus pneumoniae isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells in 1 cm322, 0mm;

a cell suspension of a pure culture of Streptococcus fecalis, isolated from affected organs from dead nutria from local epizootic focus in a nutrient medium with a title 4-5 billion microbial cells

1 cm3
22,0
glucose2,0
formalin1,5
aluminium hydroxidethe rest of it.

When this ratio of the components of the vaccine associated against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria has a weak immunogenic activity in some animals at the place of administration of the drug causes a slight irritation.

Table 1
Comparative evaluation of the efficacy of the vaccine
VaccineDose of vaccine in

cm3
Method of introductionImmunobiological properties
Number of nutria in the experience (goal)The presence of vaccine-related complicationsThe duration of immunity (months)Protection (%)
Prototypetwice

1st dose of 1.0 cm3< / br>
2nd dose of 2.0 cm3
Intramuscularly1500Oppression, chromate, refusing feeds in 2-3 days660-70
Popnedeleva method1.0 cm3Inside the muscle 1500no990-100

From the table it is seen that the proposed vaccine associated against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria has significant advantages in comparison with vaccine prototype.

Vaccine associated against colibacillosis, salmonellosis, streptococcosis and Enterococcus infection nutria containing formalin, aluminum hydroxide and tumor - cell suspension in pure cultures of Escherichia coli, Salmonella typhimurium and Streptococcus fecalis, obtained by selection of the affected organs from dead nutria from local epizootic focus, slurry preparation, sowing on differential diagnostic environment, isolation of pure cultures, separate growing them in meat-peptone broth with glucose to a concentration of microbial cells 4-5 billion in 1 cm3and mixed in equal proportions in the following ratio, wt.%:

a cell suspension of a pure culture of Escherichia coli,
isolated from affected organs from dead nutria
local epizootic focus in nutritional

environment titer 4-5 billion Mick is one of the cells in 1 cm 318,0-21,0;

a cell suspension of pure culture
Salmonella typhimurium allocated
of the affected organs from dead nutria
local epizootic focus
in a nutrient medium with a title 4-5 billion
microbial cells in 1 cm318,0-21,0;
a cell suspension of a pure culture of Streptococcus pneumoniae
isolated from affected organs from dead nutria from
local epizootic focus in a nutrient medium

with a title 4-5 billion microbial cells in 1 cm318,0-21,0;

a cell suspension of a pure culture of Streptococcus fecalis,
isolated from affected organs from dead nutria
local epizootic focus in a nutrient medium

with a title 4-5 billion microbial cells

1 cm318,0-21,0
glucose 2,0-1,0
formalin2,0-1,5
aluminium hydroxiderest



 

Same patents:

FIELD: chemical-pharmaceutical industry, biochemistry, chemistry of peptides.

SUBSTANCE: invention relates to biologically active latarcin peptides possessing antimicrobial effect that can be used in biotechnology and medicine. Method for preparing antimicrobial latarcin peptides with reduced hemolytic activity by chemical or biotechnological method involves preliminary modeling the space structure of the parent latarcin peptide with high hemolytic activity in its α-helical configuration and change of hydrophobic amino acid residues for hydrophilic residue in the synthesis process when hydrophobic amino acids Ile7 and Phe10 are replaced for hydrophilic amino acids Gln7 and Lys10. After modeling the space structure of the parent latarcin peptide in its α-helical configuration measurement of hydrophobic properties of peptide is carried out additionally and with taking into account the molecular hydrophobic potential value in each point of peptide surface and detection of hydrophobic clusters and amino acid residues localized in them followed by identification of the most effective hydrophilic amino acid residues for using in the synthesis process. Method provides preparing peptides with significantly reduced hemolytic properties and to decrease cytotoxicity of latarcin peptides.

EFFECT: improved preparing method of peptides.

3 tbl, 2 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to a preparation used in treatment of mycosis and suppurative infections in animals and humans. The preparation represents propolis 10% alcoholic tincture containing additionally ichthyol in the concentration 8-12% of solution volume. Composition consisting of propolis alcoholic extract and ichthyol is used topically with break for 0.5-1 day. Invention provides enhancing effectiveness in treatment of mycosis complicated by suppurative infection and to reduce treatment period.

EFFECT: enhanced and valuable medicinal properties of preparation.

4 tbl, 2 ex

FIELD: biotechnology, microbiology, immunology.

SUBSTANCE: invention proposes peptide from N. meningitides eliciting a sequence SEQ ID NO:10 that is used in treatment or diagnosis. Also, invention proposes polynucleotide encoding this peptide, a host-cell expressing peptide, microorganism, vaccine and antibody showing specificity to peptide proposed. Invention can be used in medicine.

EFFECT: valuable medicinal properties of peptide.

16 cl, 2 tbl

FIELD: organic chemistry, pharmacy.

SUBSTANCE: invention relates to compound of the formula (I): wherein (a) each R1 is chosen independently from hydrogen atom and alkoxy-group; (b) R2 represents hydrogen atom; (c) each R3 and R4 is chosen independently of one another from hydrogen atom, alkyl, alkynyl, heteroalkyl group, aryl; or R3 and R4 in common with nitrogen atom bound with them form heteroaryl or heterocycloaryl substitute optionally substituted with one or more hydroxo-group, carboxyl group, keto-, thioketo-, phenyl group, alkyl, heteroalkyl group, heteroaryl, heterocycloalkyl, spirocycloalkyl and their combinations; (d) each R5 and R6 represents hydrogen atom; or optical isomers, diastereomers and enantiomers represented by above given formula, and their pharmaceutically acceptable salts also. Also, invention describes using compound of the formula (I) for preparing a pharmaceutical composition possessing antibacterial activity and antibacterial pharmaceutical composition containing the safety and effective amount of compound of the formula (I) and a pharmaceutically acceptable carrier. Invention provides synthesis of novel compounds possessing useful biological properties.

EFFECT: valuable properties of compounds and pharmaceutical composition.

7 cl, 37 ex

FIELD: veterinary microbiology.

SUBSTANCE: invention proposes vaccine comprising inactivated bacterial suspension of Pasteurella multicida of serological variants A,B and D and adjuvant. As P. multicida of serological variants A, B and D invention uses P. multicida of serological variants A, B and D showing activity of soluble surface antigens in the passive hemagglutination reaction as 1:(256-4096), 1:(512-8192) and 1:(256-4096), respectively, and in the following ratio of components, wt.-%: Pasteurella multicida of serological variants A, B and D taken in the mass ratio = 1:(0.8-1.2):(0.8-1.2), 45-55, and adjuvant, the balance. Vaccine shows high activity and prolonged storage period.

EFFECT: improved and valuable properties of vaccine.

2 cl, 1 tbl, 10 ex

FIELD: pharmaceutical industry.

SUBSTANCE: method comprises washing sea-buckthorn (hippophae rhamnoides L.) seeds with water, drying of washed seeds, grinding of dried seeds into powder having specified particle size, extraction of ground dried seeds with methanol, filtration of resulting extract to separate from solids, distillation of filtered extract in vacuum evaporator, and drying of concentrated crude extract to obtain fraction showing antibacterial and antioxidant activity.

EFFECT: increased antibacterial and antioxidant activities.

9 cl, 6 ex

Improved separation // 2311183

FIELD: biochemical methods.

SUBSTANCE: invention provides a method for binding and separating at least one component from a body fluid. Body fluid, such as whole blood, is passed through integral separating matrix without displacing components according their sizes from the matrix, the latter having porous structure with pore size within a range of 5 to 500 μm and active surface between 0.5 and 10 m2. During passage, at least one component of the body fluid binds to at least one functional group in the matrix. Matrix is prepared by one of following methods: caking, molding, or foaming. Use of bile acid residue immobilized of a carrier is proposed to eliminate a component from aqueous solution containing it. Invention further provides device for selective binding of at least one component from body fluid comprising case with inlet and outlet and at least one separation matrix, said matrix being rigid and integral during passage of the body fluid therethrough.

EFFECT: achieved selectivity in separation of at least one component from a body fluid.

32 cl, 4 dwg, 2 tbl, 35 ex

FIELD: organic chemistry, medicine, pharmacology, pharmacy.

SUBSTANCE: invention relates to an antibacterial composition representing a complex of polyvinylpyrrolidone and metronidazol of the formula (I) wherein n = 76-276; m = 5-40, and containing 9-19% of metronidazol. Also, the invention relates to a method for preparing the indicated complex. The proposed composition provides maintaining the concentration of metronidazol at the therapeutic level for 48 h.

EFFECT: improved and valuable medicinal and pharmaceutical properties of composition.

3 cl, 5 tbl, 5 ex

FIELD: veterinary science, veterinary pharmacology.

SUBSTANCE: the present innovation deals with applying 3-O-acetyl-4"-O-isovaleryl-tylosine or its pharmacologically acceptable acidic-additive salt as an active agent for obtaining the desired veterinary preparation for treating and preventing Lawsonia-induced infections in swine, particularly, in case when this veterinary preparation is being a fodder additive or drinking water additive. It has been, also, suggested to apply veterinary medicinal preparation for treating and preventing Lawsonia-induced infections in swine that contains as active ingredients in the mixture of 3-O-acetyl-4"-O-isovaleryl-tylosine or its pharmacologically acceptable acidic-additive salt and tetracycline, at weight ratio ranged 1:5 up to 1:10 in which, particularly, tetracycline is being either chlorotetracycline or oxytetracycline.

EFFECT: higher efficiency of therapy and prophylaxis.

4 cl, 6 ex, 10 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes antibacterial agent that comprises moxifloxacin as a medicinal substance immobilized on polymeric carrier. As a polymer carrier the agent comprises nanoparticles of size 100-800 nm of lactic acid polymer/polymers and/or copolymer/copolymers of lactic acid and glycolic acid wherein the content of glycolic acid in indicated polymers is up to 50 mole% and wherein molecular mass of indicated polymers and copolymers is from 5 to 300 kDa. Also, agent comprises potassium cholesteryl sulfate or sodium glycocholate and a water-soluble natural or synthetic polymeric stabilizing agent of molecular mass 70 kDa, not above, chosen from group involving polyvinyl alcohol, polyvinylpyrrolidone, poloxamer, poloxamine and serum albumin and a filling agent in the amounts given in the invention claim. Agent can comprise additionally water as a solvent or water-containing mixtures. Invention provides the directed delivery of moxifloxacin to pathology focus and to regulate the rate of its releasing from polymeric matrix that provides reducing used doses of antibiotic, deceasing toxic effects and allows overcoming the resistance of infection pathogens.

EFFECT: improved and valuable properties of agent.

2 cl, 3 dwg, 4 ex

FIELD: microbiology, in particular production of associated pertusis, diphtheria, and tetanum vaccine.

SUBSTANCE: claimed method includes blending of pertusis component, diphtheria and tetanum anatoxins; mixture sorption on aluminum hydroxide; mixture dosage into container, mixture lyophilizing and container sealing. As pertusis component cell-free pertusis anatoxin in concentration of 40-50 mug/ml is used. Mixture of cell-free pertusis anatoxin, diphtheria and tetanum anatoxins is sorbed on aluminum hydroxide. Then polyoxydonium as immunomodulator in amount of 0,5-0,52 mug/g in introduced into abovementioned mixture, mixture is held for 18-20 h at 4-10°C, sucrose is added up to finish concentration and mixture is held for 1 h at 4-10°C.

EFFECT: vaccine of decreased reactogenicity.

2 ex, 1 tbl

FIELD: microbiology.

SUBSTANCE: the resent innovation deals with mixing pertussis component, diphtheric and tetanus anatoxins and sorption of the mixture upon aluminum hydroxide followed by dosing the mixture into the tank, freeze drying the mixture and hermetic sealing of this tank, moreover, as pertussis component one should apply cell-free pertussis anatoxin; as for mixing cell-free pertussis anatoxin, diththeric and tetanus anatoxins it should be carried out simultaneously at availability of phosphate-buffered physiological solution; the mixture obtained should be kept for 1 h at about 4-10°C with subsequent sorption upon aluminum hydroxide; just before freeze drying the mixture should be supplemented with saccharose up to final concentration being 9-10.5%, then the mixture should be mixed and kept at about 4-10C for 1 h. The innovation enables to achieve decreased reactogeneity.

EFFECT: higher efficiency.

2 ex, 4 tbl

FIELD: veterinary microbiology, biotechnology.

SUBSTANCE: vaccine comprises inactivated purified chlamydium antigens from strains of species Chlamydia psittaci: MZ-89 - a pathogen of chlamydiosis meningoencephalitis in calves, 250 - a pathogen of chlamydiosis abortion in cows and SK-89 - a pathogen of chlamydiosis conjunctivitis in calves, These strains are grown in chicken embryo yolk and allantois envelopes simultaneously and taken in the ratio 0.25:0.25:0.25, respectively, and in the concentration of chlamydia 16-18 mg/ml adsorbed on potash alum and emulsified in oily-lanoline adjuvant with the content of 0.2% glutaraldehyde as a preserving agent. Proposed vaccine possesses broad immunogenic activity and broad spectrum of antigenicity in different clinical forms of diseases in cattle and sheep and goats.

EFFECT: enhanced and valuable properties of vaccine.

9 tbl, 4 ex

FIELD: biotechnology.

SUBSTANCE: vaccine comprises as antigens the cell suspension of pure cultures of pathogens of coli-bacteriosis Escherichia coli, salmonellosis Salmonella typhimurium and streptococcosus Streptococcus pneumoniae obtained by selection of damaged organs from dead nutrias and inoculation of cultures on differential-diagnostic media. Isolated pure cultures are grown separately in beef-extract broth with glucose to the concentration of microbial cells 4-5 billions in 1 cm3 followed by their mixing in equal ratio. Vaccine comprises formalin and aluminum hydroxide in the following ratio of components, wt.-%: cell suspension of pure culture of coli-bacteriosis pathogen Escherichia coli isolated from a local epizootic focus in nutrient medium with a titer 4-5 billions of microbial cells in 1 cm3, 24.0-29.0; cell suspension of pure culture of salmonellosis pathogen Salmonella typhimurium isolated from a local epizootic focus in nutrient medium with a titer 4-5 billions of microbial cells in 1 cm3, 24.0-29.0; cell suspension of pure culture of streptococcosus pathogen Streptococcus pneumonia isolated from a local epizootic focus in nutrient medium with a titer 4-5 billions of microbial cells in 1 cm3, 24.0-29.0; glucose, 1.0-2.0; formalin, 1.5-2.0, and aluminum hydroxide, the balance. Proposed vaccine shows high immunogenicity, high specificity and harmless.

EFFECT: valuable properties of vaccine.

1 tbl, 5 ex

FIELD: veterinary medicine.

SUBSTANCE: vaccine comprises as antigens cell suspension of pure cultures of a streptococcosus pathogen Streptococcus pneumoniae and an enterococcal pathogen Streptococcus fecalis isolated from suspension and prepared from damages organs of dead nutrias from the local epizootic focus wherein these cultures are grown separately in beef-extract broth with glucose with the concentration of microbial cells 4-5 billions in 1 cm3 and mixed in equal ratio. Also, vaccine comprises formalin and aluminum hydroxide in the following ratio of components, wt.-%: cell suspension of pure culture of streptococcosus pathogen Streptococcus pneumoniae isolated from a local epizootic focus in the nutrient medium with a titer 4-5 microbial cells in 1 cm3, 38.0-41.5; cell suspension of pure culture of enterococcal infection pathogen Streptococcus fecalis isolated from a local epizootic focus in the nutrient medium with a titer 4-5 billions of microbial cells in 1 cm3, 38.0-41.5; glucose, 1.0-2.0; formalin, 1.5-2.0, and aluminum hydroxide, the balance. Vaccine is harmful and possesses high specificity and effectiveness.

EFFECT: valuable properties of vaccine.

1 tbl, 5 ex

FIELD: biotechnology, microbiology.

SUBSTANCE: vaccine comprises cell suspension of pure cultures of Escherichia coli as coli-bacteriosis pathogen, Salmonella typhimurium as salmonellosis pathogen and Streptococcus faecalis as enterococcus pathogen as antigens and prepared by selection of damaged organs from dead nutrias from local epizootic focus, preparing suspension, inoculation in differential diagnostic media, isolation of pure cultures of pathogens. Their culturing is carrying out separately in beef-extract broth with glucose up to the concentration 4-5 billions microbial cells/1 cm3 and mixed in equal ratios. Vaccine comprises formalin and aluminum hydroxide in the following ratio of component, wt.-%: cell suspension of pure culture of Escherichia coli as pathogen of coli-bacteriosis isolated from local epizootic focus in nutrient medium with titer value 4-5 billions microbial cells/1 cm3, 24.0-29.0; cell suspension of pure culture of Salmonella typhimurium as pathogen of salmonellosis isolated from local epizootic focus in nutrient medium with titer value 4-5 billions microbial cells/1 cm3, 24.0-29.0; cell suspension of pure culture of Streptococcus faecalis as pathogen of enterococcus infection isolated from local epizootic focus in nutrient medium with titer value4-5 billions microbial cells/1 cm3, 24.0-29.0; glucose, 1.0-2.0; formalin, 1.5-2.0, and aluminum hydroxide, the balance. Vaccine shows high immunogenicity, high specificity and safety.

EFFECT: valuable properties of vaccine.

1 tbl, 5 ex

FIELD: biotechnology, microbiology.

SUBSTANCE: invention relates to a method for preparing harmless, specific, highly immune, inactivated, mixed vaccine against coli-bacteriosis, salmonellosis and streptococcosis in nutria wherein method involves using antigens, inactivation and addition of adjuvant. Method involves selection of damaged organs from dead nutrias in local epizootic focus and preparing suspension from these organs followed by inoculation in differential diagnostic media. Pure cultures of coli-bacteriosis, salmonellosis and streptococcosis pathogens are isolated. Cultures Escherichia coli, Salmonella typhimurium and Streptococcus pneumoniae are grown separately in beef-extract broth with addition of 0.2% of glucose and with titer value 4-5 billions microbial cells/1 cm3. Inactivation is carried out by addition of formalin in the final concentration 0.4-0.6%. Then cultures are kept at temperature 37°C for 72-96 h and mixed their in equal ratio. Then aluminum hydroxide solution is added in the amount 20% to volume, stirred thoroughly, packaged and sealed. Method provides preparing harmless, immunogenic and highly specific vaccine.

EFFECT: improved preparing method.

1 tbl, 1 ex

FIELD: biotechnology, microbiology.

SUBSTANCE: method involves selection of damaged organs from dead nutrias from local epizootic focus and preparing suspension from these organs. Then method involves inoculation in differential diagnostic media and isolation of pure cultures of pathogens. Cultures Streptococcus pneumoniae and Streptococcus faecalis are grown in beef-extract broth with addition glucose to final 0.2% concentration and with titer value 4-5 billions microbial cells/1 cm3 and inactivated by addition of formalin to final concentration 0.4-0.6% and kept at temperature 37°C for 72-96 h. Cultures are mixed in equal ratios, aluminum hydroxide solution is added in the amount 15% to volume, stirred thoroughly and sealed. Method provides preparing harmless, highly immune and highly specific vaccine.

EFFECT: improved preparing method.

1 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: for manufacturing an associated vaccine it is necessary to select affected organs in dead nutrias from local epizootic focus for the purpose to prepare the suspension and fulfill inoculation onto differentially-diagnostic media. One should isolate pure cultures and separately grow the cultures of salmonellosis agents Salmonella typhimurium and Escherichia coli in beef-extract broth at addition of 0.2%-glucose at the titer being about 4-5 bln. microbial cells/cu. cm followed by inactivation due to applying formalin up to 0.4-0.6%-final concentration to be kept at 37°C for about 72-96 h. Cultures should be mixed at equal ratios, then aluminum hydroxide solution should be applied at the quantity of 20% against the culture volume to be then thoroughly mixed, packed and sealed. The innovation enables to obtain safe, specific and high-immunogenic vaccine.

EFFECT: higher efficiency.

1 ex, 1 tbl

FIELD: veterinary medicine.

SUBSTANCE: for manufacturing an associated vaccine it is necessary to select affected organs in dead nutrias from local epizootic focus for the purpose to prepare the suspension and fulfill inoculation onto differentially-diagnostic media. One should isolate pure cultures and separately grow the cultures of salmonellosis agents Salmonella typhimurium and enterococcal infection Streptococcus fecalis in beef-extract broth at addition of 0.2%-glucose at the titer being about 4-5 bln. microbial cells/cu. cm followed by inactivation due to applying formalin up to 0.4-0.6%-final concentration to be kept at 37°C for about 72-96 h. Cultures should be mixed at 1:2 ratio, then aluminum hydroxide solution should be applied at the quantity of 20% against the culture volume to be then thoroughly mixed, packed and sealed. The innovation enables to obtain safe, specific and high-immunogenic vaccine.

EFFECT: higher efficiency.

1 ex, 1 tbl

FIELD: veterinary, vaccines.

SUBSTANCE: claimed vaccine contains as antigens pure culture cell suspension of causal organisms of salmonellosus Salmonella typhimurium and enterococcus infection Streptococcus fecalis, obtained by sampling of damaged organs of fallen nutrias from local epizootic focus, suspension preparation, seeding on differential diagnostic media, isolation of causal organism pure cultures. Culturing is carried out separately in meat-and-peptone broth with glucose at microbial cell concentration of 4-5 bln per 1 cm3, cells are mixed in ratio of 1:2, formalin and aluminum hydroxide are introduced in the next component ratio (mass %): pure culture cell suspension of causal organisms of salmonellosus Salmonella typhimurium isolated from local epizootic focus in broth with titer of 4-5 bln per 1 cm3 22.5-27.5; pure culture cell suspension of causal organisms of enterococcus infection Streptococcus fecalis isolated from local epizootic focus in broth with titer of 4-5 bln per 1 cm3 50.5-55.0-27.5; glucose 2.0-1.0; formalin 2.0-1.5; and balance: aluminum hydroxide.

EFFECT: associated vaccine with increased specificity and effectiveness without negative side effects.

1 tbl, 5 ex

Up!